With Odanacatib Filing Pushed Back, Merck Reports Flat Top-Line Growth In 2012
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s delay of filing an NDA for its osteoporosis drug odanacatib surprised analysts, but Merck remained mum on its reasoning in a year-end earnings call on Feb. 1.